We scan new podcasts and send you the top 5 insights daily.
Inconclusive HRD assays frequently occur following neoadjuvant chemotherapy due to a lack of residual tumor tissue at interval debulking. Rather than indicating an assay failure, the absence of assessable tissue demonstrates an exceptional pathological response to initial systemic treatment.
Hormone receptor-positive (HR+) HER2+ breast cancers often show lower rates of pathologic complete response (pCR) to pre-surgical therapy. This is due to their slower-growing biology, not treatment ineffectiveness. Clinicians should recognize this nuance and not assume a worse prognosis based on pCR alone in this subtype.
A strong response to neoadjuvant chemotherapy can eliminate viable tumor cells, making subsequent HRD testing impossible. It is critical to obtain an adequate biopsy for molecular testing before initiating systemic therapy to guide future maintenance decisions.
In neoadjuvant therapy, a patient's long-term outcome is better predicted by stopping tumor DNA shedding (ctDNA clearance) than by achieving pathologic complete response (pCR), the traditional gold standard. This redefines what constitutes a successful treatment response before surgery.
If multiple attempts at HRD biomarker testing are indeterminate, a strong clinical response to platinum-based neoadjuvant chemotherapy can serve as a surrogate for HRD positivity. This clinical observation can support the decision to treat the patient as HRD-positive and offer a PARP inhibitor.
HRD status is a continuous variable with an arbitrary diagnostic cutoff rather than a strict binary result. When a patient achieves a complete pathological response to neoadjuvant platinum, clinicians consider PARP inhibitors even if formal genomic testing returned negative.
A negative liquid biopsy (ctDNA) result for HER2 amplification does not prove a patient is HER2-negative. The test's sensitivity is limited by tumor fraction in the blood. While a positive ctDNA result is highly specific and trustworthy, a negative result is simply 'not detected' and requires a tissue biopsy to definitively determine HER2 status for treatment decisions.
In neoadjuvant trials, patients who fail to achieve a pathologic complete response are scientifically invaluable. Their resected tumors, which survived initial treatment, provide critical tissue to study resistance mechanisms. This allows researchers to inform the development of better combination therapies for all stages of disease.
When an HRD test is inconclusive due to insufficient tumor tissue after neoadjuvant chemotherapy, it can paradoxically indicate a very strong response to treatment and high platinum sensitivity, as there is little to no residual tumor to analyze.
In neoadjuvant breast cancer treatment, patients with residual cancer post-therapy remain at high risk of recurrence (10-20%) even if their ctDNA tests are negative. This finding suggests that the physical presence of residual disease is a critical factor, and ctDNA status alone cannot justify forgoing additional adjuvant therapy in this cohort.
The interpretation of ctDNA is context-dependent. Unlike in the adjuvant setting, in the neoadjuvant setting, remaining ctDNA positive post-treatment signifies that the current therapy has failed. These high-risk patients need a different therapeutic approach, not an extension of the ineffective one.